Authors
Latest:
Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast CancerJoan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference.
Latest:
Joan Lockhart on Fostering Oncology Nursing EducationJoan Such Lockhart, PhD, RN, AOCN, FAAN, from the Duquesne University School of Nursing, discusses resources currently available to help strengthen the oncology training of nurses.
Latest:
Joanna Morales on Common Cancer Related Legal IssuesJoanna Morales from the Cancer Legal Resource Center on Common Cancer Related Legal Issues
Latest:
Dr. Blum on Takeaways from ABC Trials for Breast CancerJoanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the key takeaways from the phase III ABC (anthracyclines in early breast cancer) trials, which compared docetaxel plus cyclophosphamide versus anthracycline/taxane-based chemotherapy regimens in patients with high-risk, HER2-negative breast cancer.
Latest:
Day in the Life of an Oncology/Hematology Fellowship Program DirectorTrainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.
Latest:
Dr. Mortimer on the Potential Benefit of Tucatinib Plus ADCs in HER2+ Breast CancerJoanne Mortimer, MD, discusses the potential benefit of tucatinib plus antibody-drug conjugates in HER2-positive breast cancer.
Latest:
Dr. Xiu on HR Expression in Uterine CarcinosarcomaJoanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.
Latest:
Dr Bellmunt on Avelumab Maintenance in Advanced Urothelial Carcinoma With Low Tumor BurdenJoaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.
Latest:
Dr. Lorch on the Treatment of Medullary Thyroid CancerJochen H. Lorch, MD, director, Thyroid Cancer Center, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the current treatment landscape of medullary thyroid cancer.
Latest:
Dr. Barr on Temozolomide and Capecitabine in Neuroendocrine TumorsJodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).
Latest:
Compatibility Check: Can Precision Medicine and Pathways Co-Exist?One of the most widely talked about trends in healthcare is precision medicine, which uses detailed genetic information about a patient’s cancer to more precisely treat the disease, effectively targeting the tumor. This heightened awareness raises an important question: are precision medicine and pathways compatible?
Latest:
Dr. O'Sullivan on Safety Profile of Radium-223Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Therapy for ALK+ NSCLCJoel Neal, MD, an assistant professor of medicine and oncology at Stanford Medicine, discusses whether, if approved by the FDA, alectinib (Alecensa) will become the frontline standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC).
Latest:
Dr. Neal on the FDA Approval of Mobocertinib in EGFR Exon 20 Insertion+ NSCLCJoel Neal, MD, PhD, discusses the FDA accelerated approval of mobocertinib in EGFR exon 20 insertion–positive non–small cell lung cancer.
Latest:
Dr. Silver Talks About Advances in Treatment of Hematological CancersJoel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.
Latest:
Joel Stettler on Procedures for Fall-Risk PatientsJoel Stettler, BSN, RN, OCN, Moffitt Cancer Center, discusses procedures implemented at his institution for patients who are at risk for falls.Â
Latest:
Dr. Johan Vansteenkiste on Atezolizumab in NSCLCJohan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric CancerJohanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.
Latest:
Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRCJohanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).
